Search Results for: Analisi sull’uso dei farmaci anti-osteoporotici in sette database europei

Per colite ulcerosa, sclerosi multipla e fibrosi cistica

Greenpeace riporta l’analisi dell’Imperial College e Lshtm

Purpose
Adolescents living with HIV (ALHIV) are a priority population for achieving global HIV prevention and treatment targets but experience poorer outcomes than adults. Long-term follow-up is essential to understand their transition into adulthood. By linking self-reported survey data with routine laboratory records, we established a social science clinical cohort of ALHIV South Africa’s Eastern Cape to explore factors shaping their long-term health and well-being.

Participants
Eligible participants were adolescents who were part of a three-wave quantitative cohort of ALHIV and not living with HIV (2014–2018) and had consented (adolescent and caregiver) to having their self-reported interviews linked with routine health records (n=1563). Adolescents were recruited into the existing three-wave cohort through clinic and community-based methods (97% enrolment, >90% retention over three waves). Between 2019 and 2022, we abstracted laboratory test records from the National Health Laboratory Services database for all eligible participants, with matching based on demographic variables. Individuals with at least one HIV-related record form our ‘lifelong social science cohort’, a total of 956 ALHIV (852 of 1107 ALHIV and 104 of 456 HIV-uninfected).

Findings to date
A total of 32 886 laboratory test records from 2004 to 2023 were matched through three rounds of data extraction, using iteratively refined record-linking searches. Most records were viral load (8864) and CD4 count (6801) results, with a median of 10 (IQR: 7–14) and 8 (IQR: 5–11) tests per matched adolescent, respectively. Overall, 956 of 1563 adolescents (61%) were successfully linked to laboratory data, including 852 of 1107 (77%) ALHIV. Analysis of the matched cohort survey-laboratory data provided several insights. Self-reported antiretroviral therapy adherence was strongly associated with viral suppression, even after adjusting for covariates. The strongest predictors of suppression were not reporting missed doses in the past 3 days, past week and not missing clinic appointments in the past year. Among adolescent girls and young women living with HIV, access to safe and affordable facilities, and kind and respectful staff were associated with a higher likelihood of multiple improved HIV-related outcomes, including viral suppression. Exposure to sexual and intimate partner violence predicted worse viral load outcomes among adolescents.

Future plans
This integrated prospective cohort provides an opportunity to characterise long-term HIV treatment outcomes among ALHIV in Africa. We will investigate how individual, familial, community and healthcare experiences in childhood, and adolescence shape these outcomes. Since the COVID-19 pandemic happened during the period of matched data, we will also investigate the potential effect of the COVID-19 pandemic on adolescent HIV treatment outcomes, with potential subgroup analyses for individuals with available COVID-19-related results.

L’esperienza maturata con le App per la salute è il punto di partenza per l’introduzione di soluzioni digitali più avanzate, come le Terapie Digitali, un ambito per il quale in Italia non esiste ancora una normativa di riferimento, nonostante diverse proposte di legge che stanno cercando di regolamentarne l’uso: il 45% dei medici specialisti italiani sarebbe disposto a prescriverle, se fosse possibile. Sono alcuni dei risultati della ricerca dell’Osservatorio Life Science Innovation del Politecnico di Milano, presentata oggi durante il convegno “Life Science: costruire il futuro tra digitale, algoritmi e nuove competenze”.

Un nuovo farmaco per la colite ulcerosa da moderata a grave e nuove indicazioni di farmaci per la sclerosi multipla e la fibrosi cistica. Sono alcuni dei trattamenti che saranno rimborsati dal Servizio sanitario nazionale (Ssn) a seguito delle decisioni assunte dal Consiglio di Amministrazione dell’Aifa nella seduta dell’8 luglio 2025.
In totale i farmaci interessati sono 7: 1 nuova molecola chimica, 1 medicinale generico e 5 farmaci già rimborsati per altre indicazioni.

Censis, con screening, consegna farmaci, e prenotazioni Cup

Il rapporto del Censis, recapito farmaci e screening in testa

Stroke, Ahead of Print. BACKGROUND:While the efficacy of statins, which are cholesterol-lowering agents, in preventing subarachnoid hemorrhage (SAH) has been examined in experimental animal models and some clinical studies, findings remain inconclusive. This study aimed to investigate the association between statin use and the risk of SAH.METHODS:We conducted a large population-based case-control study using data from the Japanese Health Insurance Claims Database from January 2005 to August 2021. This nationwide database includes the data of individuals aged 0 to 74 years. Cases were defined as patients hospitalized with a first diagnosis of SAH (International Classification of Diseases, Tenth Revisioncode I60) during this period. Four controls per case were randomly selected and matched by age, sex, and follow-up period using incidence density sampling. Statin exposure (use, recency, and duration) was evaluated before the incidence of SAH. Conditional logistic regression, adjusted for patient characteristics, was used to assess the association between statin use and SAH risk. We also investigated whether this association varies with a history of hypertension, diabetes, cerebrovascular disease, unruptured intracranial aneurysms, and the use of antihypertensive medications.RESULTS:The study identified 3498 cases and 13 992 matched controls. Statin use was reported in 12.2% of SAH cases and 12.7% of the controls. After adjusting for patient characteristics, statin use was associated with a significantly reduced risk of SAH (adjusted odds ratio, 0.81 [95% CI, 0.69–0.95]). The association was significantly influenced by a history of hypertension or cerebrovascular disease (Pinteraction=0.042 and 0.042, respectively).CONCLUSIONS:Statin use was significantly associated with a reduced risk of SAH. These findings suggest that statins may play a role in the prevention of SAH, particularly in patients with a history of hypertension or cerebrovascular disease.

This Viewpoint explores how a publicly searchable US Food and Drug Administration database of medical device labels could improve decision-making, transparency, and public health.

Gravi problemi affliggono il Servizio sanitario nazionale. Un complesso di considerazioni e analisi fondate su fonti certificate è la premessa per affrontare adeguatamente il problema della carenza di personale sanitario,…

10 molecole assorbono 70% consumi. Ampie differenze tra regioni

10 molecole assorbono 70% consumi. Ampie differenze tra regioni

Message Subepithelial lesions (SLEs) are often detected incidentally during endoscopic examination. They represent a heterogeneous group of lesions including non-neoplastic and neoplastic lesion, the most relevant of which may be gastrointestinal stromal tumour (GIST) and neuroendocrine tumours (NET). We report the biggest SELs database (4901 cases) on histology characteristics of different SELs resected endoscopically (mean size 1.45 cm, range 0.80–1.90 cm). In the oesophagus, leiomyomas comprised 95.7% of all lesions, while, in the stomach, GIST tumours were the predominant lesions (40.3%), but mostly in body (39.8%) and fundus (46.2%), much less so in the antrum (13.6%). Most of the gastric GISTs were of very low or low risk (93.1%). In the antrum, non-neoplastic lesions were most prominent (48.5%), and 20.1% lipomas were lipomas. Only a few lesions were resected in the duodenum (n=208), mostly non-neoplastic (35.6%), as were in the colorectum (n=592), with the vast majority being rectal NETs (55.9%)….

Circulation, Volume 152, Issue 1, Page 81-84, July 8, 2025.

Objective
A synthesis and appraisal of the recommendations for biomarkers in practice guidelines concerning sepsis is required to consolidate evidence-based practice. We generated an evidence gap map (EGM) on the use of biomarkers for managing adults with sepsis.

Design
Scoping review.

Data sources
MEDLINE, Guidelines International Network, Pan American Health Organization, Trip Database and UpToDate were searched from 2016 to March 2025.

Eligibility criteria
Guidance documents (GD) that searched at least one literature source and provided clinical recommendations for the use of biomarkers for the management (diagnosis and prognosis, including treatment response) of adults with sepsis.

Data extraction and synthesis
Two reviewers independently applied the eligibility criteria and extracted data. We used the AGREE-II (Appraisal of Guidelines for Research and Evaluation) tool to assess the GD quality. GDs that scored ≥50% on the AGREE-II ‘Rigour of development’ domain were considered robust. We also applied the GRADE (Grading of Recommendations Assessment, Development and Evaluation) system to evaluate if the recommendations were strong or conditional.

Results
We found 10 GDs, with only half (4/8) having a robust methodology. There were 31 recommendations concerning biomarkers. Among these, 24 (77.4%) recommendations were about single biomarkers, with lactate (23; 74.2%) and procalcitonin (8; 25.8%) most frequently recommended. Biomarker testing focused on prognosis in 28 (90.3%) recommendations. Overall, 16 (51.6%) recommendations were graded strong and 13 (42.0%) were conditional, which we displayed in an EGM.

Conclusions
The methodology of GDs concerning adult sepsis was poor. Our review calls for more prudent use of biomarkers in specific prognostic scenarios and in combination with standard clinical assessments. Enhancing the methodological quality of future GDs is essential to generate more valid and robust recommendations for optimising patient care.

Introduction
Primary dysmenorrhoea (PD) is the most common gynaecological condition among young women and is associated with significant socioeconomic repercussions. It is unclear which works best for pain relief when pharmacological and non-pharmacological interventions are compared. This systematic review and network meta-analysis (NMA) will aim to compare and rank the effects of pharmacological and non-pharmacological interventions in patients with PD.

Methods and analysis
Randomised controlled trials of pharmacological and non-pharmacological interventions for PD will be identified via a search of the PubMed, Cochrane Library, Web of Science, Embase, Scopus database and Google Scholar search engine until September 2025. The primary outcome will be a change in pain intensity among patients with PD, while the secondary outcomes include health-related quality of life, symptoms of depression and anxiety, and treatment-related adverse events. Two independent reviewers will perform document screening, study selection and data extraction. The methodological quality of the included studies will be assessed using the Cochrane Risk of Bias tool (V.2). The RevMan, Stata and Aggregate Data Drug Information System software will be used to perform a pairwise meta-analysis and Bayesian NMA in a random-effects model. The certainty of the evidence will be rated using the Grading of Recommendations, Assessment, Development, and Evaluation System.

Ethics and dissemination
This systematic review protocol is exempt from ethical approval as it involves analysis of previously published data. The findings of this review will be submitted to peer-reviewed journals.

Trial Registration number
CRD42024543573.